Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2025-03-11 Major Shareholding Noti…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
FR 250311 notification de transparence PR BR.pdf
Major Shareholding Notification Classification · 99% confidence The document is a 'Notification de transparence' (Transparency Notification) issued by UCB SA, announcing a change in the shareholding of BlackRock, Inc. Specifically, it details that BlackRock's stake crossed the 5% threshold downwards following a divestment. This type of filing, which reports changes in significant share ownership (crossing thresholds), directly corresponds to the definition of Major Shareholding Notification (MRQ). The text explicitly mentions the law regarding the 'publicity of important shareholdings' and details the number of voting rights and financial instruments held by the entity and its related parties, confirming the nature of the filing.
2025-03-11 French
NL 250311 transparencieverklaring PR BR.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparantieverklaring BlackRock, Inc." and explicitly states it is a notification ("kennisgeving") regarding a change in significant shareholding, referencing Article 14 of the Belgian law on the disclosure of major shareholdings. It details the exact number of voting shares and financial instruments held by BlackRock, Inc. and its affiliates, noting that the 5% threshold was crossed (specifically, the holding decreased below 5% on March 6, 2025). This content directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ' in the provided schema.
2025-03-11 Dutch
UCB PR FY 2024 Feb 27 2025 ENG.pdf
Annual Report Classification · 100% confidence The document is titled 'UCB Full-Year Report 2024' and contains comprehensive financial results, including revenue, net sales, EBITDA, and EPS for the full fiscal year. It also includes detailed management commentary, clinical pipeline updates, and sustainability information. As it provides substantive financial data and analysis for the full year, it is classified as an Annual Report (10-K equivalent). FY 2024
2025-02-27 English
UCB PR FY 2024 Feb 27 2025 FR.pdf
Earnings Release Classification · 95% confidence The document is titled 'Rapport annuel 2024 d'UCB' and contains comprehensive financial results, including revenue, EBITDA, net sales, and dividend information for the fiscal year 2024. It also provides detailed management commentary, R&D pipeline updates, and regulatory news. While it is an annual report, it functions as the primary financial disclosure for the period. Given the document length and the inclusion of substantive financial data and analysis, it is classified as an Earnings Release (ER) or Interim/Quarterly Report (IR) depending on the scope, but since it covers the full fiscal year and provides the initial announcement of these results, it fits the Earnings Release (ER) category for the initial announcement of annual results. FY 2024
2025-02-27 French
UCB PR FY 2024 Feb 27 2025 NL.pdf
Annual Report Classification · 100% confidence The document is a comprehensive financial report for the fiscal year 2024, titled 'UCB financieel jaarverslag 2024'. It contains detailed financial tables (revenue, EBITDA, earnings per share), management commentary from the CEO and CFO, and detailed updates on clinical pipelines and regulatory status. It is not a short announcement or a certification letter, but the substantive annual financial report itself. Therefore, it is classified as an Annual Report (10-K). FY 2024
2025-02-27 Dutch
UCB IAR 2024 ENG FINAL (1).pdf
Annual Report Classification · 100% confidence The document is titled 'Integrated Annual Report 2024' and explicitly states it contains the management report, corporate governance statement, sustainability statement, and financials. It covers the company's performance for the full fiscal year 2024. This aligns with the definition of an Annual Report (10-K). FY 2024
2025-02-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.